** Shares in Novo Nordisk rise around 2% after its controlling shareholder said on Saturday it had fulfilled regulatory conditions to acquire Catalent in the U.S.
** The deal involves the sale of three Catalent manufacturing sites to Novo Nordisk
** The conversion of the Catalent sites will provide Novo with much more filling capacity than is currently anticipated, J.P.Morgan analysts say
** This will allow Novo to not only ramp the U.S. supply of Wegovy faster from 2026, but also the global supply of Ozempic and the supply of Wegovy excluding the U.S. also from 2026, the broker adds
** Separately, Novo Nordisk said it plans to invest 8.5 billion Danish crowns ($1.20 billion) in a new plant in Denmark
** Novo Nordisk shares top the Copenhagen blue chip index
($1 = 7.0971 Danish crowns)
(Reporting by Boleslaw Lasocki)
((boleslaw.lasocki@thomsonreuters.com; +48 58 769 66 00;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。